Epilepsia最新文献

{"title":"Do the third-generation antiseizure medications provide the “magic bullet” for drug-resistant epilepsy? Focus on cenobamate","authors":"Patrick Kwan, Martin J. Brodie","doi":"10.1111/epi.18306","DOIUrl":"10.1111/epi.18306","url":null,"abstract":"<p>Achieving seizure freedom remains elusive for a substantial number of patients, particularly those designated as having drug-resistant epilepsy. Over the past 30 years, 24 new antiseizure medications (ASMs) have been developed and licensed in the United States and Europe, some of which offer improved safety and tolerability profiles.<span><sup>1, 2</sup></span> However, landmark studies conducted in Glasgow, Scotland, on individuals with newly diagnosed epilepsy have suggested that the proportion of patients with uncontrolled epilepsy has not decreased significantly during this time. In the most recent updated analysis of the Glasgow cohort,<span><sup>3</sup></span> which included 1795 adolescents and adults who began ASM treatment between 1982 and 2012, the use of second-generation drugs increased from 21% in the first decade to 74% in the last. Despite this shift in availability and choice, the probability of achieving seizure freedom—defined as no seizures for at least the previous year—has remained unchanged across three consecutive decades. In this latest update, 64% of patients were seizure-free, a proportion identical to that reported in the earlier, smaller study undertaken in the same clinical setting and published in 2000.<span><sup>4</sup></span> These findings were confirmed in a recent systematic review and meta-analysis of observational studies involving 10 109 children and adults with newly diagnosed epilepsy, published between 1995 and 2021.<span><sup>5</sup></span> The pooled proportion of those achieving seizure freedom for 1 year at the last follow-up was 68% (95% confidence interval [CI]: 63%–72%), with outcomes not linked to the publication year or the earliest date of cohort recruitment. This lack of fundamental progress in treatment outcomes has underpinned the relentless search for the “magic bullet” that will result in long-term seizure freedom for the majority of people designated as having drug-resistant epilepsy.</p><p>The arrival of a number of third-generation ASMs over the past decade has sparked recent optimism that a breakthrough in epilepsy drug treatment may be on the horizon. These ASMs, omitting those limited to licensing for rare epilepsy syndromes, include lacosamide, eslicarbazepine, perampanel, brivaracetam, and cenobamate—listed in chronological order of approval. Among these, cenobamate arguably appears the most promising, as reviewed in this special supplement of articles.</p><p>In this supplement, Sperling and coworkers highlight the risks associated with uncontrolled seizures, particularly those with a focal onset leading to bilateral tonic–clonic seizures, which pose the highest risk for sudden unexpected death in epilepsy (SUDEP). They then summarize the impressive efficacy and tolerability of cenobamate in initial clinical trials and the high proportion of patients achieving seizure freedom, which was sustained in an open-label extension study. It is important to note that the reduction in seizu","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":"66 S1","pages":"1-3"},"PeriodicalIF":6.6,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain perfusion imaging by arterial spin labeling predicts postsurgical seizure freedom in pediatric focal lesional epilepsy: A pilot study.","authors":"Antonio Giulio Gennari, Luca Gaito, Dorottya Cserpan, Raimund Kottke, Niklaus Krayenbühl, Andrea Rüegger, Ruth O' Gorman Tuura, Georgia Ramantani","doi":"10.1111/epi.18375","DOIUrl":"https://doi.org/10.1111/epi.18375","url":null,"abstract":"<p><strong>Objective: </strong>This study was undertaken to determine whether integrating arterial spin labeling (ASL) perfusion imaging into presurgical planning improves postsurgical seizure outcomes in children with pharmacoresistant focal lesional epilepsy associated with focal cortical dysplasia (FCD) or low-grade epilepsy-associated tumors (LEATs).</p><p><strong>Methods: </strong>We retrospectively analyzed magnetic resonance imaging (MRI) scans from 18 children (median age = 4.8 years, interquartile range = 1.9-11.5) who underwent resection for FCD- or LEAT-associated pharmacoresistant epilepsy, with at least 1 year of follow-up. All patients underwent presurgical ASL imaging along with pre- and postsurgical structural MRI. Image postprocessing, including segmentation and coregistration, assessed the completeness of resection of the anatomical lesion and ASL-derived perfusion changes. DICE similarity scores measured the alignment of pre- to postsurgical segmentations, and the residue ratio assessed the percentage of presurgical segmentation remaining postresection. These metrics were then correlated with postsurgical seizure outcomes.</p><p><strong>Results: </strong>Fourteen (78%) patients achieved seizure freedom, and 13 (72%) had complete lesion resection. Qualitative analysis showed that complete inclusion of the perfusion changes within the resection cavity significantly correlated with seizure freedom (p = .009), whereas complete resection of the anatomical lesion did not (p = .57). Quantitative analysis indicated that higher alignment of the perfusion changes with the resection cavity, measured by the DICE score, was significantly associated with seizure freedom (p = .043), whereas alignment between lesion and resection was not (p = .44). Larger residual perfusion volumes significantly correlated with seizure recurrence (p = .008).</p><p><strong>Significance: </strong>Incorporating ASL perfusion imaging into presurgical evaluation may better delineate the epileptogenic zone, potentially improving postsurgical seizure outcomes. These findings support ASL as a valuable complementary tool in surgical planning for pharmacoresistant pediatric focal lesional epilepsy.</p>","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: Interim results after 24-week observational period from the BLESS study.","authors":"Simona Lattanzi, Fedele Dono, Giuseppe d'Orsi, Alfredo D'Aniello, Mariangela Panebianco, Paolo Bonanni, Carlo Di Bonaventura, Elisa Montalenti, Antonio Gambardella, Federica Ranzato, Giada Pauletto, Elena Tartara, Angela La Neve, Francesca Bisulli, Giampaolo Vatti, Patrizia Pulitano, Claudio Liguori, Giovanni Assenza, Alfonso Giordano, Pietro Pignatta, Vincenzo Belcastro, Michela Cecconi, Simone Beretta, Chiara Pizzanelli, Marianna Pezzella, Massimo Gangitano, Maurizio Elia, Rosaria Renna, Catello Vollono, Angelo Pascarella, Luciana Tramacere, Giovanni De Maria, Daniela Audenino, Maria Pia Pasolini, Loretta Giuliano, Rosita Galli, Gionata Strigaro, Monica Puligheddu, Angelo Labate, Pietro Penza, Stefano Quadri, David Stokelj, Giovanni Boero, Elisa Fallica, Monica Santo Sabato, Giovanni Falcicchio, Nicoletta Foschi, Michela Procaccini, Valentina Villano, Gabriele Camattari, Fabiano Mele, Barbara Roncari, Giancarlo Di Gennaro","doi":"10.1111/epi.18357","DOIUrl":"https://doi.org/10.1111/epi.18357","url":null,"abstract":"<p><strong>Objective: </strong>Cenobamate is an antiseizure medication (ASM) with a dual mechanism of action that was recently approved for the treatment of focal seizures in adults. This analysis aimed to describe the outcomes at 12 and 24 weeks after starting cenobamate therapy in a real-world setting.</p><p><strong>Methods: </strong>BLESS [NCT05859854] is an ongoing, observational, retrospective and prospective cohort study to evaluate the real-world effectiveness and safety of adjunctive cenobamate in adults with uncontrolled focal epilepsy. Subgroup analysis was performed in subjects with 2 to 3 previous ASMs (early users) and those with >3 previous ASMs (late users).</p><p><strong>Results: </strong>The second interim analysis of the BLESS study included 388 participants with a median (interquartile range) age of 43.0 (31.0-54.0) years. They had a median of 6.0 (4.0-9.0) prior ASMs and a median of 7.2 (3.0-20.6) monthly seizures at baseline. The median monthly seizure frequency was reduced by 59.9% (19.2%-87.3%) from baseline to 24 weeks; 229 (59.0%) subjects had a ≥50% seizure frequency reduction, and 44 (11.3%) showed sustained seizure freedom. The proportion of participants taking ≤2 concomitant ASMs increased from 217 (56.5%) at baseline to 239 (65.7%) at 24 weeks. Among the early users (n = 76, 19.6%), the median reduction in monthly seizure frequency at 24 weeks was 78.0% (50.0-97.1%), and 76.3% of subjects had a ≥50% response rate. The frequency of adverse drug reactions (ADRs) was 5.3% and 23.4% in early and late users. The most frequent ADRs were somnolence, dizziness, and balance disorder; after the occurrence of ADRs, 63.5% of participants maintained the prescribed dose, and 5.2% permanently discontinued treatment.</p><p><strong>Significance: </strong>Cenobamate was effective in reducing seizure frequency in a real-world setting and showed a manageable safety profile. The treatment with cenobamate also reduced the burden of concomitant ASMs in both early and late users.</p>","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ENX-101, a GABA_A receptor α2,3,5-selective positive allosteric modulator, displays antiseizure effects in rodent seizure and epilepsy models.","authors":"Jordi Serrats, Krishna C Vadodaria, William Brubaker, Melissa Barker-Haliski, H Steve White, Alexis Evrard, Corinne Roucard, Eve Taylor, Kimberly E Vanover, Stephen Cunningham, Vikram Sudarsan, Michael A Rogawski","doi":"10.1111/epi.18340","DOIUrl":"https://doi.org/10.1111/epi.18340","url":null,"abstract":"<p><strong>Objective: </strong>γ-Aminobutyric acid type A (GABA_A) receptor positive allosteric modulators (PAMs) that lack α-subunit selectivity, including benzodiazepines such as diazepam, exhibit antiseizure actions in animal models and in humans. ENX-101 is a deuterated analog of the ⍺2,3,5-selective GABA_A receptor PAM L-838,417. The purpose of this study was to characterize the α-subunit selectivity of ENX-101 and evaluate its antiseizure potential in preclinical seizure and epilepsy models.</p><p><strong>Methods: </strong>ENX-101 potentiation of GABA chloride current responses in cells expressing recombinant GABA_A receptors were evaluated using an automated patch clamp assay. Antiseizure effects of ENX-101 were examined in the mouse 6 Hz test at 32 and 44 mA, amygdala kindled rats, and Genetic Absence Epilepsy Rat from Strasbourg (GAERS).</p><p><strong>Results: </strong>ENX-101 displayed partial PAM activity with respect to diazepam at GABA_A receptors containing α2, α3, or α5 subunits but did not enhance GABA responses of GABA_A receptors containing α1 subunits. ENX-101 (30, 100, and 300 mg/kg, i.p.) and diazepam protected most animals in the 6 Hz model at 32 mA but was less effective at 44 mA. In amygdala kindled rats, ENX-101 (1-100 mg/kg, p.o.) reduced behavioral seizure severity and afterdischarge duration in a dose-dependent manner. ENX-101 (0.075-100 mg/kg, p.o.) caused dose-dependent, persistent (>130 min) inhibition of spontaneous spike-and-wave discharges (SWDs) in GAERS, whereas diazepam transiently inhibited discharges. ENX-101 did not cause motor impairment, as measured by performance in the rotarod assay.</p><p><strong>Significance: </strong>ENX-101 is an α2,α3,α5-selective GABA_A receptor PAM that has high potency and partial efficacy. The drug is highly effective in rodent seizure and epilepsy models. ENX-101 is most potent in the GAERS model of absence epilepsy, and active in the 6 Hz model and amygdala kindled rats. These results demonstrate that a partial, subtype-selective GABA_A receptor PAM has activity in translationally validated preclinical epilepsy screening models. Clinical evaluation of ENX-101 as a treatment for focal and generalized epilepsies is warranted.</p>","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scoping review of single-item global rating scales utilized in epilepsy research: Patterns of use, challenges, and recommendations.","authors":"Ann Subota, Mandavi Kashyap, Yasamin Mahjoub, Guillermo Delgado-García, Colin B Josephson, Samuel Wiebe","doi":"10.1111/epi.18333","DOIUrl":"https://doi.org/10.1111/epi.18333","url":null,"abstract":"<p><p>SIGRs (single-item global ratings) are gaining popularity among clinicians and health researchers as efficient tools to assess patient-reported outcomes. There has been no systematic assessment of domains explored, methodological aspects, and validation efforts of SIGRs in epilepsy. We aimed to critically appraise and provide recommendations on the use and reporting of SIGRs in epilepsy research. We performed a systematic scoping review using the Joanna Briggs Institute's recommendations. The Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) method was used to search five electronic databases (MEDLINE, Embase, PsycINFO, CINAHL, and Cochrane Register of Controlled Trials) from 1980 to present day. We included English-language studies utilizing SIGRs that assessed health aspects (concept) in people with epilepsy of all ages (participants), in all settings (context), containing ≥30 patients, and using SIGRs with continuous or categorical responses in any study design. Abstract and full-text review was conducted independently by two reviewers; disagreements were resolved through consensus. Standardized data abstraction was used. Of 16 417 citations, we included 289 studies, involving 114 584 patients who underwent 747 unique measurements using SIGRs. Use increased over time; 30% were published in the last 4 years, and 51% used 1 SIGR (range 1-23 SIGRs). Commonly assessed domains were overall health (24.2%) and seizure-related aspects (23.5%), whereas 37% measured perceived change. Most studies used SIGRs descriptively (80.1%). Numerous SIGR formats were used (most commonly Likert-like, 73.3%). Ad hoc SIGRs without validation occurred frequently (45.6%). Stem questions were absent in 9.5% of measures, and only 6.5% reported SIGR measurement properties. SIGRs are widely used and increasingly prevalent in epilepsy research to assess diverse domains across various formats. However, many SIGRs suffer from poor reporting and methodological limitations. We provide a comprehensive catalog of SIGRs and offer recommendations to improve their use in research and clinical practice.</p>","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep-related hypermotor epilepsy-No longer controversial.","authors":"Francesca Bisulli, Samuel F Berkovic, Ingrid E Scheffer, Edouard Hirsch, Lino Nobili, Federica Provini, Paolo Tinuper, Luca Vignatelli","doi":"10.1111/epi.18364","DOIUrl":"https://doi.org/10.1111/epi.18364","url":null,"abstract":"","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Widespread decoupling of spindles and slow waves in temporal lobe epilepsy.","authors":"Katharina Schiller, Nicolás von Ellenrieder, Daniel Mansilla, Chifaou Abdallah, Kassem Jaber, Alfonso Garcia-Asensi, John Thomas, Erica Minato, Jean Gotman, Birgit Frauscher","doi":"10.1111/epi.18359","DOIUrl":"10.1111/epi.18359","url":null,"abstract":"<p><strong>Objective: </strong>Memory impairment is common in people with temporal lobe epilepsy (TLE). Recent studies in healthy subjects showed a positive correlation between sleep spindles coupled to slow waves (SWs) and memory performance. We aimed to determine differences in spindle-SW coupling in TLE patients compared to healthy controls using combined high-density electroencephalography and polysomnography.</p><p><strong>Methods: </strong>The study population consisted of 20 patients (12 female, 36.5 ± 9.9 years old) with unilateral drug-resistant TLE (10 left temporal) and 20 age- and sex-matched controls (12 female, 31.2 ± 6.3 years old). Spindles (10-16 Hz, .5-3 s) and SWs (.5-4 Hz) were automatically detected during all N2 and N3 epochs using validated detectors. Coupling of spindles with SWs was defined as overlap between both detected events.</p><p><strong>Results: </strong>Coupled spindle-SW rates (per minute) were globally reduced in patients with TLE compared to healthy controls (median = .18 [interquartile range (IQR) = .08-.36] vs. .35 [IQR = .24-.46], p = .014, d = -.46). This reduction was also found for coupled fast spindle (12-16 Hz)-SW (.06 [IQR = .02-.13] vs. .18 [IQR = .07-.25], p = .013, d = -.46) and slow spindle (10-12 Hz)-SW rates (.11 [IQR = .04-.23] vs. .19 [IQR = .13-.27], p = .034, d = -.40). Within TLE patients, there was no local difference between the coupling rates in the lobe with the epileptic focus compared to the contralateral side (.09 [IQR = .02-.13] vs. .07 [IQR = .02-.13], p = .18). The effect size of the reduction was stronger in early than late sleep for both N2 and N3 sleep (early N2 d = -.50 vs. late N2 d = -.39; early N3 d = -.53 vs. late N3 d = -.47).</p><p><strong>Significance: </strong>Despite a focal epileptic generator, patients with unilateral TLE showed a widespread decoupling between sleep spindles and SWs that was most prominent in early sleep. As coupling was shown to be associated with neuropsychological performance in healthy people, this global decoupling may constitute one potential mechanism of poor memory performance in people with TLE.</p>","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variants in ATP6V0C are associated with Dravet-like developmental and epileptic encephalopathy.","authors":"Marlene Rong, Paula T Marques, Quratulain Zulfiqar Ali, Ricardo Morcos, Ilakkiah Chandran, Farah Qaiser, Rikke S Møller, Allan Bayat, Guido Rubboli, Elena Gardella, Miriam S Reuter, Tristan T Sands, Ingrid E Scheffer, Amy Schneider, Annapurna Poduri, Elaine Wirrell, Rima Nabbout, Joseph Sullivan, Kette Valente, Stéphane Auvin, Kelly G Knupp, Andreas Brunklaus, Ángel Aledo-Serrano, Danielle M Andrade","doi":"10.1111/epi.18346","DOIUrl":"https://doi.org/10.1111/epi.18346","url":null,"abstract":"<p><strong>Objective: </strong>Dravet syndrome (DS) is a developmental and epileptic encephalopathy. Diagnosis is clinical, but ~90% of patients have pathogenic variants in SCN1A. ATP6V0C has recently been proposed as a novel candidate gene for epilepsy, with or without developmental delay. Here we describe two adult patients with a clinical diagnosis of DS associated with ATP6V0C variants.</p><p><strong>Methods: </strong>Patients with developmental and epileptic encephalopathies were evaluated by physicians who are experts in DS, and their clinical diagnosis was correlated with genetic findings. A subgroup of those patients with DS but without known genetic causes were evaluated through gene panels, whole exome sequencing, and chromosome microarray. Phenotype was determined by pediatric and adult chart reviews, interviews, and physical examinations.</p><p><strong>Results: </strong>Of 753 patients with DS, two unrelated individuals with classic features of DS during childhood and adulthood were identified with heterozygous de novo missense variants in ATP6V0C (c.319G > C, p.(Gly107Arg) and c.284C > T, p.(Ala95Val), respectively). Both variants were absent in normal populations and computational prediction algorithms suggested deleterious effects on protein structure and/or function. No disease-causing variants in other genes previously associated with DS were found.</p><p><strong>Significance: </strong>Here we describe two adult patients with Dravet-like syndrome and pathogenic/likely pathogenic variants in ATP6V0C. We propose that abnormal ATP6V0C function can, at the severe end of the clinical spectrum, be associated with Dravet-like phenotype. This is relevant, as these patients would not qualify for disease-modifying antisense nucleotide or gene therapies targeting SCN1A.</p>","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epilepsia – March 2025 Announcements","authors":"","doi":"10.1111/epi.18341","DOIUrl":"https://doi.org/10.1111/epi.18341","url":null,"abstract":"&lt;p&gt;\u0000 \u0000 &lt;b&gt;18th Latin American Summer School on Epilepsy&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;7–15 March 2025&lt;/p&gt;&lt;p&gt;São Paulo, Brazil&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;1st Pediatrics Commission Symposium&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;21–24 March 2025&lt;/p&gt;&lt;p&gt;São Paulo, Brazil&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;7th ILAE School on EEG in the First Year of Life&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;26–27 April 2025&lt;/p&gt;&lt;p&gt;Sanya City, Hainan, China&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;ILAE School on Neuroimaging 2025&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;15–17 May 2025&lt;/p&gt;&lt;p&gt;Potsdam, Germany&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;5th African Epilepsy Congress&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;16–18 May 2025&lt;/p&gt;&lt;p&gt;Lusaka, Zambia&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;15th ILAE School for Neuropathology and Neuroimaging in Epilepsy&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;31 July – 3 August 2025&lt;/p&gt;&lt;p&gt;Campinas, São Paulo, Brazil&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;XVIII Workshop on Neurobiology of Epilepsy (WONOEP 2025)&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;25–29 August 2025&lt;/p&gt;&lt;p&gt;Portugal&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;36th International Epilepsy Congress&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;30 August – 3 September 2025&lt;/p&gt;&lt;p&gt;Lisbon, Portugal&lt;/p&gt;&lt;p&gt;\u0000 &lt;b&gt;2026&lt;/b&gt;\u0000 &lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;15th ILAE School on Pre-Surgical Evaluation for Epilepsy and Epilepsy Surgery&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;19–23 January 2026&lt;/p&gt;&lt;p&gt;Brno, Czech Republic&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;16th European Epilepsy Congress&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;5–9 September 2026&lt;/p&gt;&lt;p&gt;Athens, Greece&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;Epidemiology of Epilepsy in Kenya&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;10 March 2025&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;4th Rome Debate on DEEs&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;15 March 2025&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;World Neuroscience and Psychiatry Conference 2025 (WNPC25)&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;8–9 March 2025&lt;/p&gt;&lt;p&gt;Bangkok, Thailand&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;19th World Congress on Controversies in Neurology&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;20–22 March 2025&lt;/p&gt;&lt;p&gt;Prague, Czech Republic&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;13th Trinational Conference of the German and Austrian Society for Epileptology and the Swiss Epilepsy League&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;26–29 March 2025&lt;/p&gt;&lt;p&gt;Salzburg, Austria&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;1–5 April 2025&lt;/p&gt;&lt;p&gt;Vienna, Austria &amp; Online&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;International Congress on Structural Epilepsy &amp; Symptomatic Seizures 2025&lt;/b&gt;\u0000 \u0000 &lt;/p&gt;&lt;p&gt;2–4 April 2025&lt;/p&gt;&lt;p&gt;Gothenburg, Sweden&lt;/p&gt;&lt;p&gt;\u0000 \u0000 &lt;b&gt;EPIPE","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":"66 3","pages":"942-943"},"PeriodicalIF":6.6,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/epi.18341","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between the time course of Burden of Amplitudes and Epileptiform Discharges scores and relapse in children with infantile epileptic spasms syndrome.","authors":"Masahiro Umeda, Tohru Okanishi, Satoru Kobayashi, Shinji Itamura, Yoshimichi Hirayama, Wataru Matsumura, Yuto Arai, Ayataka Fujimoto, Yoshihiro Maegaki","doi":"10.1111/epi.18347","DOIUrl":"10.1111/epi.18347","url":null,"abstract":"<p><strong>Objective: </strong>For patients with infantile epileptic spasms syndrome (IESS) who have achieved remission of epileptic spasms (ES), indicators of how well the electroencephalographic (EEG) state should be maintained during follow-up are not available. We hypothesized that the time course of the Burden of Amplitudes and Epileptiform Discharges (BASED) score after ES remission is associated with ES relapse. This study aimed to investigate the association between ES relapse and BASED scores at the time of initial ES remission and during the subsequent follow-up period.</p><p><strong>Methods: </strong>We collected clinical and digital EEG data at four hospitals from patients with IESS who achieved initial ES remission. The BASED score was evaluated using EEGs obtained before remission, during remission, and after remission. The scoring was performed independently by the three reviewers, who were blinded to each other's scores. We analyzed the associations between clinical factors, BASED score, maximum BASED score, and ES relapse.</p><p><strong>Results: </strong>Data were collected from 44 patients aged 4-8 months at disease onset, which included 33 nonrelapsed and 11 relapsed patients. We assessed the BASED score of 262 EEGs. Structural etiology (p = .002) and the development of seizure other than ES (p = .04) were positively associated with ES relapse. Whereas BASED score before and at remission was not associated with relapse, a maximum BASED score of ≥3 during the postremission period was significantly associated with relapse (p < .001, odds ratio = 100). In multivariate analysis, only maximum BASED score ≥3 during this period remained significantly associated with relapse (p = .001, odds ratio = 76). The interrater reliability of the BASED score was high, with a quadratically weighted kappa coefficient of .93.</p><p><strong>Significance: </strong>A maximum BASED score of ≥3 during postremission indicates a risk for ES relapse in patients with IESS.</p>","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":" ","pages":""},"PeriodicalIF":6.6,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}